US Patent 5,349,945: Scope, Claim Construction, Expiration, and Aerosol-Inhaler Patent Landscape

US Patent 5,349,945 covers a mechanical dose-indicator system integrated into a metered-dose aerosol inhaler. Its core combination is a reciprocating valve-actuation structure, a rotatable indicator carrying a circumferential or annular rack, and a worm-gear mechanism driven by movement associated with the aerosol vial or support block. The patent issued on September 20, 1994, and its ordinary United States patent term expired on September 20, 2011, assuming no unusual term adjustment or extension. It therefore presents no current U.S. blocking right for new products.

What does US Patent 5,349,945 protect?

The patent protects an aerosol dispenser that counts or indicates actuation events through mechanical movement of the canister and valve-support assembly.

The central architecture requires all of the following:

A housing with a patient port.
Accommodation for an aerosol vial equipped with a metered-dose valve.
A support block with:
- a socket receiving the valve stem; and
- an orifice communicating with the socket and patient port.
Reciprocal movement between the support block and the aerosol vial.
A rotatable indicator positioned so its rotational axis is parallel to the reciprocal movement.
A circumferential or annular rack on the indicator.
A worm gear engaging the rack.
A movement-detecting member that responds to relative movement between the vial and support block.
Transmission of that movement to the worm gear, causing indicator rotation.

The invention is therefore narrower than a generic “dose counter” or “inhaler with an indicator.” It requires a particular mechanical arrangement involving reciprocal valve movement and worm-driven rotation of a rack-bearing indicator.

How should independent claim 1 be construed?

Claim 1 is the principal apparatus claim. Its scope can be divided into five functional groups.

Aerosol dispenser and valve interface

The housing must accommodate an aerosol vial fitted with a metered-dose dispensing valve. The claim does not identify a particular active ingredient, propellant, canister size, or dose strength.

The support block must receive the valve stem through a socket. Its orifice must communicate with both the socket and the patient port. This language links the valve outlet to the inhalation pathway and distinguishes the claimed structure from a counter mounted separately from the aerosol flow path.

Reciprocal movement

The support block must move reciprocally relative to the aerosol vial. The claim does not require the support block itself to move in an absolute sense. Relative movement is sufficient.

This permits multiple implementations, including:

a stationary vial with a moving support block;
a moving vial with a stationary support block;
both components moving, provided that relative reciprocal movement occurs.

Claims 8 and 9 expressly develop these alternatives.

Rotatable indicator

The indicator must rotate around an axis parallel to the reciprocal movement of the support block relative to the vial. This orientation is a material limitation. A counter that rotates around an axis perpendicular to the canister movement may avoid claim 1 unless another claim construction or equivalent-structure argument applies.

Rack and worm gear

The indicator must include a circumferential rack, and the worm gear must engage that rack. The rack may be annular under claim 2, and claim 3 places the annular rack around the support block.

A conventional linear ratchet, sliding scale, rotary cam, electronic sensor, or digital display would not literally satisfy the rack-and-worm limitation.

Movement detection and transmission

A movement-detecting member must respond to the reciprocal movement and cause the worm gear to rotate. The claim requires a mechanical transmission relationship, not merely an indicator that changes whenever the inhaler is actuated.

The movement detector may be a projecting finger, the vial itself, or another structure capable of selectively engaging the worm mechanism.

How do claims 2 through 6 narrow the mechanical counter?

Claim	Added limitation	Practical effect
2	Indicator has an annular rack	Limits the rack to a ring-like configuration
3	Annular rack rotates about the support block	Ties the rack directly to the valve-support structure
4	Teeth, spacer gap, and spacer block prevent more than one full rotation	Adds an anti-overrun arrangement and a defined counting range
5	Worm gear has a shaft with an integral worm and ratchet wheel	Requires a combined worm-and-ratchet drive
6	Worm and ratchet wheel are integral	Confirms a one-piece or integral mechanical relationship

Claim 1 is broader than claims 2 through 6 because it does not expressly require an annular rack, spacer gap, spacer block, or integral ratchet wheel. A product may therefore fall outside the narrower dependent claims while still raising a claim 1 issue if it retains the broader circumferential-rack and worm-drive arrangement.

What movement-detection arrangements are covered?

Claims 7 through 10 address alternative ways to detect actuation.

Projecting finger fixed relative to the vial

Under claim 8, the projecting finger is fixed to the aerosol vial while the vial moves relative to the support block. The finger selectively engages the worm gear during the actuation cycle.

This arrangement is directed to a counter driven by the canister’s movement.

Projecting finger fixed relative to the support block

Under claim 9, the finger is fixed relative to the support block, and the vial moves to engage it. This is the inverse mechanical arrangement.

The vial as the movement-detecting member

Claim 10 broadly identifies the aerosol vial itself as the movement-detecting member. This claim can capture designs in which the canister directly contacts or actuates the worm mechanism without a separately identified projecting finger.

The existence of these alternatives makes the patent more robust against simple relocation of the actuator. A design-around would generally need to change the counter architecture, not merely move the contact finger from the vial to the support block.

What visibility and safety features are protected?

Claims 11 and 12 cover alternative display locations:

claim 11 requires a housing viewing port through which the indicator is visible;
claim 12 allows visibility through the patient port.

Claim 13 adds a mechanism preventing unwanted indicator movement. The claim is functionally drafted and could encompass a detent, brake, resilient retaining feature, friction element, anti-reverse structure, or another mechanism that prevents unintended rotation.

Claim 14 covers a pre-inhalation actuation-prevention mechanism. The claim does not specify whether this is a breath-actuated lock, airflow-dependent interlock, trigger mechanism, or mechanical sequencing system. Its scope depends heavily on the specification and prosecution history because “means to prevent actuation ... prior to inhalation” may raise means-plus-function issues under 35 U.S.C. § 112(f).

What formulation and product combinations are covered?

Claims 15 and 16 extend the apparatus claims to combinations with an aerosol vial.

Claim 15 covers the dispenser combined with an aerosol vial. Claim 16 adds a self-propelled pharmaceutical formulation containing a medicament.

The formulation limitation is broad. It does not identify:

a specific active pharmaceutical ingredient;
a specific propellant;
a particle-size distribution;
an excipient;
a concentration;
a therapeutic indication; or
a particular dosing regimen.

Claim 16 therefore does not create composition-of-matter protection for a drug. Its value was tied to the combination of the patented dispenser, vial, and pharmaceutical formulation.

When did US Patent 5,349,945 lose exclusivity?

Event	Date
Patent issued	September 20, 1994
Default term for pre-June 8, 1995 applications	17 years from issue
Ordinary expiration	September 20, 2011
Current status for new U.S. conduct	Expired

The governing transition rule for patents issuing from applications filed before June 8, 1995 generally applies a 17-year term from grant, subject to the statutory transition provisions. See 35 U.S.C. § 154(c)(1).

Because the patent expired more than a decade ago:

no current generic product requires a license under this patent;
no current inhaler launch can be blocked by this patent;
a new Paragraph IV certification against this patent would have no practical role;
a current infringement suit would not support prospective exclusion based on post-expiration conduct.

The analysis would differ only for historical conduct occurring before expiration or for an unusual surviving claim involving pre-expiration infringement.

What is the Orange Book status of US Patent 5,349,945?

US Patent 5,349,945 is principally a device patent. The claims focus on the inhaler housing, valve-support block, dose indicator, worm gear, rack, and mechanical actuation system.

A device patent is not automatically an Orange Book-listed patent. Orange Book listing generally concerns patents that claim an approved drug substance, drug product, formulation, composition, or method of use for the approved product. The patent’s combination claims involving an aerosol vial and medicament do not, by themselves, establish Orange Book eligibility.

The patent should therefore be treated as a historical device patent rather than as a current Orange Book barrier. Its expiration also removes any practical exclusivity effect even if a related product listing had existed.

Does the patent create Paragraph IV or biosimilar risk?

Paragraph IV risk

No current Paragraph IV risk arises from an expired patent. Paragraph IV certifications address listed patents that are still capable of delaying approval or supporting exclusionary relief.

During the patent’s life, a generic MDI manufacturer could have assessed whether its inhaler used:

a reciprocating valve-support structure;
an annular or circumferential rack;
a worm gear;
a movement-triggered ratchet;
a visible mechanical counter; or
the claimed actuation interlock.

A generic device using an electronic counter, a linear counter, a different rotary drive, or a non-worm transmission would have had stronger non-infringement positions.

Biosimilar risk

The patent has no meaningful biosimilar relevance. Biosimilar applications concern biologic products under the Public Health Service Act. The claimed technology is an aerosol dispenser for a metered-dose vial, not a biologic molecule or biologic manufacturing process.

The relevant competitive threat was generic or follow-on inhaler competition, not biosimilar entry.

How strong was the patent estate?

The patent was technically focused but commercially relevant during its enforceable term.

Strengths

Claim 1 combines the inhaler actuation interface and dose-counter mechanism.
Claims 7 through 10 cover multiple locations for the movement detector.
The annular rack and worm-drive arrangement can provide compact mechanical counting.
Claims 11 through 14 extend coverage to visibility and actuation-control features.
Claim 16 links the device to a medicated aerosol formulation without limiting the product to one active ingredient.

Weaknesses

The claims require a worm gear and circumferential rack.
The claimed rotational axis has a specified relationship to reciprocal movement.
Electronic and non-worm counters are natural design-around options.
The formulation claims do not protect a drug substance or a specific pharmaceutical formulation.
“Means to prevent” language in claim 14 may depend on disclosed structures under § 112(f).
The patent is expired, eliminating present enforcement value.

The patent was strongest against compact mechanical inhalers using a coaxial or surrounding annular counter. It was weaker against inhalers using electronic sensing, linear dose strips, optical detection, magnetic sensing, or counters driven by airflow rather than canister movement.

What manufacturing and IP barriers did the patent create?

The patent could have affected manufacturers in four areas:

Tooling for an annular rack and integrated worm-ratchet assembly.
Precise alignment between the valve stem, support block, rack, and worm gear.
Reliable one-dose indexing without double counting.
Preventing actuation before inhalation while maintaining acceptable airflow and dose delivery.

The manufacturing barrier was primarily mechanical engineering and assembly control. The patent did not create a barrier to manufacturing the active ingredient, propellant, canister, or pharmaceutical formulation independently.

A manufacturer could reduce risk through:

an electronic or optical counter;
a linear rather than annular display;
a cam or pawl instead of a worm gear;
an indicator driven by airflow;
a counter detached from the valve-support block; or
a different rotational-axis arrangement.

Which companies were likely affected by this patent class?

The relevant commercial group included manufacturers of:

pressurized metered-dose inhalers;
mechanical dose counters;
inhaler actuator housings;
respiratory drug-device combinations; and
contract-manufactured aerosol dispensers.

The patent’s value would have depended on whether a company controlled both the inhaler actuator and the pharmaceutical product. A drug company could avoid direct device manufacture but still face supply-chain or combination-product licensing issues if its designated inhaler used the claimed mechanism.

Because the patent has expired, current competitors can use the claimed mechanical concepts without obtaining a license under US Patent 5,349,945. Separate patents covering improved dose counters, breath-actuation systems, valve structures, formulation technology, or specific inhaler products may still apply.

What patent litigation and settlement issues affect the patent?

The patent’s expiration changes the litigation analysis.

Current litigation

An expired patent cannot provide a current injunction against a newly launched inhaler. Any present dispute would more likely concern:

pre-expiration sales;
contract or license obligations;
ownership of related improvement patents;
trade secrets;
regulatory exclusivity; or
a separate, later-expiring patent family.

Historical litigation

A complete historical litigation assessment requires docket-level review of federal cases, International Trade Commission proceedings, and European or United Kingdom counterparts. The claim text alone does not establish whether the patent was litigated, licensed, or included in a settlement.

Settlement agreements

No settlement right or continuing restriction follows merely from the existence of an expired patent. Any continuing obligation would have to arise from the language of a separate license or settlement agreement.

How does this patent compare with modern inhaler patents?

Technology	Covered by US 5,349,945?	Main distinction
Mechanical annular rack and worm counter	Potentially yes	Core claimed architecture
Linear dose counter	Generally no	Different rack and indicator geometry
Electronic dose counter	Generally no	No claimed worm-rack mechanism
Optical or magnetic actuation sensor	Generally no	Different movement detection
Airflow-triggered counter	Usually no	Counter is not driven by claimed reciprocal vial movement
Breath-actuated lock	Potentially, if combined with claim 14 structure	Must also satisfy claim 1
Drug formulation alone	No	Claims are device-centered
Biologic product	No	No biologic or biosimilar claim scope

Key Takeaways

US Patent 5,349,945 claims a mechanical dose-indicating aerosol dispenser.
Claim 1 requires a reciprocal valve-support arrangement, circumferential rack, worm gear, and movement-triggered rotation.
Claims 2 through 6 narrow the counter to annular, anti-overrun, and integral worm-ratchet configurations.
Claims 7 through 10 cover alternative movement-detector arrangements involving the vial or support block.
Claims 11 through 14 address display visibility, anti-movement control, and pre-inhalation actuation prevention.
Claims 15 and 16 cover dispenser-vial combinations, but do not provide active-ingredient or composition-of-matter protection.
The patent issued on September 20, 1994, and its ordinary term expired on September 20, 2011.
It is not a current U.S. blocking patent and presents no live Paragraph IV or biosimilar risk.
Modern electronic, optical, magnetic, linear, or airflow-driven counters generally provide straightforward design-around paths.
Any current freedom-to-operate analysis must focus on later patents covering inhaler counters, valves, formulations, and combination products.

FAQs

Can a company use the worm-gear dose-counter concept today?

Yes. The expired patent no longer prevents use of its disclosed and claimed U.S. technology. Later patents covering improvements may still require separate review.

Does claim 16 protect a specific inhaled drug?

No. Claim 16 requires a self-propelled pharmaceutical formulation containing a medicament but does not identify a particular active ingredient or formulation composition.

Would a digital inhaler counter infringe claim 1?

A digital counter would generally avoid literal infringement if it lacks the claimed circumferential rack and worm gear. Other patent claims could still apply.

Does the patent cover a dry-powder inhaler?

Not on the claim language supplied. The claims require an aerosol vial equipped with a metered-dose dispensing valve, which points to a pressurized metered-dose inhaler rather than a conventional dry-powder inhaler.

Can the expired patent still affect a licensing transaction?

Only indirectly. It may remain relevant to historical ownership, royalty accounting, representations, warranties, or disputes over pre-expiration conduct. It does not ordinarily create a current exclusionary right.

References

U.S. Patent No. 5,349,945, Aerosol dispenser (issued September 20, 1994).
35 U.S.C. § 154(c)(1). Patent term transition provisions for applications filed before June 8, 1995.
U.S. Food and Drug Administration. (2023). Approved drug products with therapeutic equivalence evaluations. Center for Drug Evaluation and Research.
U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. Center for Biologics Evaluation and Research.

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
United Kingdom	9025654	Nov 26, 1990

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	9060491	⤷ Start Trial
Germany	69108929	⤷ Start Trial
European Patent Office	0559757	⤷ Start Trial
United Kingdom	9025654	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Summary for Patent: 5,349,945